TY - JOUR
T1 - Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands
T2 - version 1.0
AU - Albert, Nathalie L
AU - Preusser, Matthias
AU - Traub-Weidinger, Tatjana
AU - Tolboom, Nelleke
AU - Law, Ian
AU - Palmer, Joshua D
AU - Guedj, Eric
AU - Furtner, Julia
AU - Fraioli, Francesco
AU - Huang, Raymond Y
AU - Johnson, Derek R
AU - Deroose, Christophe M
AU - Herrmann, Ken
AU - Vogelbaum, Michael
AU - Chang, Susan
AU - Tonn, Joerg-Christian
AU - Weller, Michael
AU - Wen, Patrick Y
AU - van den Bent, Martin J
AU - Verger, Antoine
AU - Ivanidze, Jana
AU - Galldiks, Norbert
N1 - © 2024. The Author(s).
PY - 2024/10
Y1 - 2024/10
N2 - PURPOSE: To provide practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands.METHODS: This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO).RESULTS: Positron emission tomography (PET) using somatostatin receptor (SSTR) ligands can detect meningioma tissue with high sensitivity and specificity and may provide clinically relevant information beyond that obtained from structural magnetic resonance imaging (MRI) or computed tomography (CT) imaging alone. SSTR-directed PET imaging can be particularly useful for differential diagnosis, delineation of meningioma extent, detection of osseous involvement, and the differentiation between posttherapeutic scar tissue and tumour recurrence. Moreover, SSTR-peptide receptor radionuclide therapy (PRRT) is an emerging investigational treatment approach for meningioma.CONCLUSION: These practice guidelines will define procedure standards for the application of PET imaging in patients with meningiomas and related SSTR-targeted PRRTs in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers, facilitate comparability of studies, and to collect larger databases. The current document provides additional information to the evidence-based recommendations from the PET/RANO Working Group regarding the utilization of PET imaging in meningiomas Galldiks (Neuro Oncol. 2017;19(12):1576-87). The information provided should be considered in the context of local conditions and regulations.
AB - PURPOSE: To provide practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands.METHODS: This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO).RESULTS: Positron emission tomography (PET) using somatostatin receptor (SSTR) ligands can detect meningioma tissue with high sensitivity and specificity and may provide clinically relevant information beyond that obtained from structural magnetic resonance imaging (MRI) or computed tomography (CT) imaging alone. SSTR-directed PET imaging can be particularly useful for differential diagnosis, delineation of meningioma extent, detection of osseous involvement, and the differentiation between posttherapeutic scar tissue and tumour recurrence. Moreover, SSTR-peptide receptor radionuclide therapy (PRRT) is an emerging investigational treatment approach for meningioma.CONCLUSION: These practice guidelines will define procedure standards for the application of PET imaging in patients with meningiomas and related SSTR-targeted PRRTs in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers, facilitate comparability of studies, and to collect larger databases. The current document provides additional information to the evidence-based recommendations from the PET/RANO Working Group regarding the utilization of PET imaging in meningiomas Galldiks (Neuro Oncol. 2017;19(12):1576-87). The information provided should be considered in the context of local conditions and regulations.
KW - Humans
KW - Isotope Labeling
KW - Ligands
KW - Meningeal Neoplasms/diagnostic imaging
KW - Meningioma/diagnostic imaging
KW - Nuclear Medicine/standards
KW - Positron-Emission Tomography/standards
KW - Radiopharmaceuticals/therapeutic use
KW - Receptors, Somatostatin/metabolism
KW - PRRT
KW - Somatostatin receptor
KW - DOTATOC
KW - Procedure guideline
KW - SiTATE
KW - Theranostics
KW - DOTATATE
KW - Targeted radionuclide therapy
KW - Meningioma
KW - PET
UR - http://www.scopus.com/inward/record.url?scp=85196290348&partnerID=8YFLogxK
U2 - 10.1007/s00259-024-06783-x
DO - 10.1007/s00259-024-06783-x
M3 - Journal article
C2 - 38898354
SN - 1619-7070
VL - 51
SP - 3662
EP - 3679
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 12
ER -